Promising combo for advanced cancers halted early
NCT ID NCT04284488
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 25 times
Summary
This study tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors like colorectal, nasopharyngeal, and lung cancer. The goal was to find a safe dose and see if the combo could control the disease. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Foshan First People's Hospital
Foshan, Guangdong, China
-
Sun-Yat Sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The Affiliated Hospital OF Guangxi Medical University
Nanning, Guangxi, 530021, China
Conditions
Explore the condition pages connected to this study.